ACE-031 Reconstitution Calculator
A soluble activin receptor type-IIB fusion protein referenced in myostatin-pathway and muscle-research literature. This page works out concentration, volume per measured amount, syringe units and preparations per vial for a reconstituted ACE-031 preparation, plus the mass-to-molar conversions for its stated molecular weight. Everything runs in your browser; plan entries stay in this browser, with optional device-local saving and calendar export.
Also referenced as: Ramatercept, ACE031
02 / Calculated draw
Arithmetic from your entries. Confirm the product, concentration and syringe with your pharmacist or clinician before administration.
- Concentration
- —
- Amount per administration
- —
- Volume per administration
- —
- U-100 syringe marking
- —
- Whole administrations per vial
- —
- Remainder per vial
- —
Enter the vial, water and administration amounts to calculate.
Syringe capacity
Whole administrations exclude dead space, handling losses and expiry. A calculated quantity is not a guarantee of usable supply. No rounding to a nearby syringe mark is performed.
Protocol schedule
Schedule an existing prescribed or approved protocol. This tool cannot determine how often you can safely take a peptide. Frequency, dose, reconstitution, storage and discard instructions must come from the product label and your clinician or pharmacist.
04 / Your calendar
Complete your calculation and timing to build a schedule.
Calculations stay in this browser. Saving is optional and device-local. Calendar export creates a file; import it into your calendar and configure reminders there. PeptiDex does not send notifications.
| Date & time | Amount | Draw | Vial |
|---|
Measurement reference: FDA guidance on concentration, syringe size and mg/mL/unit conversion errors.
A separate worked example, step by step
This separate arithmetic example uses a 5 mg vial, 2 mL of bacteriostatic water, and a 250 mcg target amount. They are not a property of ACE-031 and not an amount anyone should draw — these figures only illustrate the arithmetic.
- Concentration. 5 mg ÷ 2 mL = 2.5 mg/mL (2,500 mcg/mL), which for ACE-031 is approximately 0.03125 mM at its stated molecular weight.
- Per syringe unit. A U-100 syringe divides 1 mL into 100 units, so one unit holds 2,500 mcg ÷ 100 = 25 mcg.
- Volume for the 250 mcg target. 250 mcg ÷ 2,500 mcg/mL = 0.1 mL, or 10 units on that syringe.
- Preparations per vial. 5,000 mcg ÷ 250 mcg = 20 preparations.
Arithmetic on a laboratory preparation, shown as a unit-conversion reference. Not medical advice, not a dosing recommendation, not an instruction for human use. The full derivation, and why the diluent volume is a choice rather than a constant, is on the main reconstitution calculator.
Mass and molar equivalents for ACE-031
Derived from the molecular weight recorded on the ACE-031 entry: ~80 kDa (glycosylated ActRIIB-Fc homodimer) — the entry states this as an approximate figure, so the equivalents below are approximate too. Concentration in molar units is what an in-vitro protocol is usually specified in.
| Quantity | Molar equivalent |
|---|---|
| 1 mg of ACE-031 | 12.5 nmol (0.0125 µmol) |
| 1 mcg of ACE-031 | 0.0125 nmol |
| A 1 mg/mL solution | 0.0125 mM (12.5 µM) |
Molar amount = mass ÷ molecular weight. Figures are shown to four significant digits and are a unit conversion, not a measurement.
Reconstitution recorded for ACE-031
Supplied as a lyophilized biologic requiring reconstitution and cold-chain storage; handled like an antibody-type protein rather than a small peptide.
Quoted from the ACE-031 entry. Amounts reported in the research literature for this compound are documented on that entry, under the disclaimer they belong with — they are not reproduced next to a calculator. Read the full ACE-031 entry.
Handling questions for ACE-031
Why is ACE-031's large size relevant to research handling?
Because ACE-031 is a ~80 kDa glycosylated Fc-fusion protein rather than a sub-10 kDa peptide, it behaves like an antibody-type biologic: it has a long circulating half-life driven by Fc recycling and requires cold-chain handling. This distinguishes its stability and dosing-interval considerations sharply from small synthetic peptides.
Answers are published on the ACE-031 entry. Educational summaries of research-literature context, not medical advice.
Continue exploring
- Full ACE-031 entry — Myostatin-pathway inhibitor
- Reconstitution calculator — the maths in full, with a second worked example
- Storage & Handling guide
- Bacteriostatic water — what it is and how it differs from sterile water
- Compare ACE-031 with another library entry